Investigation Report on Chinese Salmeterol/Ticasone Market 2021-2025
|出版商||China Research and Intelligence||商品編碼||1006920|
|出版日期||內容資訊||英文 50 Pages
|中國的Salmeterol/Ticasone市場分析 (2021年∼2025年) Investigation Report on Chinese Salmeterol/Ticasone Market 2021-2025|
|出版日期: 2021年05月21日||內容資訊: 英文 50 Pages||
中國國內的Salmeterol/Ticasone的銷售額，從2016年到2019年繼續擴大趨勢，2020年達到了約2億9677萬元。但，2020年受到新型冠狀病毒感染疾病 (COVID-19) 感染擴大的影響，自上年度變成21.59％的減少。今後，根據COVID-19結束等市場預計復歸到成長軌道，不過，也能認為受到相關專利的屆滿，多的生物相似藥產品上市。一方面為了大企業的佔有率縮小，產業整體平均價格下降，整體銷售量預計擴大。
Salmeterol/Ticasone is a compound medication used in regular treatment of asthma and chronic obstructive pulmonary disease (COPD). Its original drug was developed by GlaxoSmithKline. In 2001, Salmeterol Ticasone powder inhalation was approved to enter the Chinese market, and its indication was chronic obstructive pulmonary disease (COPD), and its trade name was SERETIDE; a new indication for asthma was added in China in 2010. SERETIDE powder inhalation has been covered in the category B medical insurance catalogs of 31 provinces, and by 2020 the manufacturers of Salmeterol/Ticasone in China is Glaxo Wellcome(formerly the welcome Foundation) and GlaxoSmithKline(France).
According to CRI's market research, the sales of Salmeterol/Ticasone have had an increasing trend in the Chinese market from 2016 to 2019.The sales revenue in 2020 was approximately CNY296.77million. However, the sales of Salmeterol/Ticasone in 2020 decreased by 21.59% compared with that in 2019 due to the COVID-19 epidemic. The CAGR for Salmeterol/Ticasone is approximately -3.82% from 2016 to 2020.
According to CRI analysis, from 2021 to 2025, the sales of Salmeterol/Ticasone in China will have a recovery growth with the improvement of the epidemic situation and normal operation of overall diagnosis and treatment in hospitals. After the patent for Salmeterol/Ticasone expired, more biosimilar drugs will appear in the market. In China, Respirent Pharmaceuticals Co. Ltd has already submitted an application for Salmeterol/Ticasone in 2021. Therefore, in the next few years, the market share for Glaxo Wellcome (formerly the wellcome Foundation) and GlaxoSmithKline (France) will gradually shrink. At the same time, with the launch of biosimilar drugs, the price will be further reduced. The price adjustment will reduce the burden on patients, thereby increasing the use and sales of Salmeterol/Ticasone.
2.3.1Gas (powder) aerosol